These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19475867)

  • 21. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials.
    Cossu G; Sampaolesi M
    Trends Mol Med; 2007 Dec; 13(12):520-6. PubMed ID: 17983835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Best practice in Duchenne muscular dystrophy.
    Buccella F; Furlong P; Hofmeister S; Vroom E
    Neuromuscul Disord; 2010 Mar; 20(3):216-7; author reply 218-9. PubMed ID: 20206518
    [No Abstract]   [Full Text] [Related]  

  • 23. Best practice in Duchenne muscular dystrophy.
    Munn MW
    Neuromuscul Disord; 2010 Mar; 20(3):216; author reply 218-9. PubMed ID: 20206519
    [No Abstract]   [Full Text] [Related]  

  • 24. Best practice in Duchenne muscular dystrophy.
    Wong BL
    Neuromuscul Disord; 2010 Mar; 20(3):217-8; author reply 218-9. PubMed ID: 20206521
    [No Abstract]   [Full Text] [Related]  

  • 25. Best practice in Duchenne muscular dystrophy.
    Topaloglu H
    Neuromuscul Disord; 2010 Mar; 20(3):218; author reply 218-9. PubMed ID: 20206522
    [No Abstract]   [Full Text] [Related]  

  • 26. Best practice in Duchenne muscular dystrophy.
    Tseng B
    Neuromuscul Disord; 2010 Mar; 20(3):217; author reply 218-9. PubMed ID: 20206523
    [No Abstract]   [Full Text] [Related]  

  • 27. Best practice in Duchenne muscular dystrophy.
    Quinlivan R
    Neuromuscul Disord; 2010 Mar; 20(3):217; author reply 218-9. PubMed ID: 20206520
    [No Abstract]   [Full Text] [Related]  

  • 28. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist.
    Ames WA; Hayes JA; Crawford MW
    Paediatr Anaesth; 2005 Jan; 15(1):3-8. PubMed ID: 15649156
    [No Abstract]   [Full Text] [Related]  

  • 30. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Exon skipping in Duchenne's muscular dystrophy].
    Nau JY
    Rev Med Suisse; 2008 Jan; 4(140):176. PubMed ID: 18309885
    [No Abstract]   [Full Text] [Related]  

  • 32. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
    Aartsma-Rus A; Corey DR
    Nucleic Acid Ther; 2020 Apr; 30(2):67-70. PubMed ID: 32043902
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on the management of Duchenne muscular dystrophy.
    Manzur AY; Kinali M; Muntoni F
    Arch Dis Child; 2008 Nov; 93(11):986-90. PubMed ID: 18667451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting RNA to treat neuromuscular disease.
    Muntoni F; Wood MJ
    Nat Rev Drug Discov; 2011 Aug; 10(8):621-37. PubMed ID: 21804598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the severity of Duchenne muscular dystrophy: implications for treatment.
    Nelson SF; Griggs RC
    Neurology; 2011 Jan; 76(3):208-9. PubMed ID: 21178098
    [No Abstract]   [Full Text] [Related]  

  • 36. RNA-targeted drugs for neuromuscular diseases.
    Ferlini A; Goyenvalle A; Muntoni F
    Science; 2021 Jan; 371(6524):29-31. PubMed ID: 33384365
    [No Abstract]   [Full Text] [Related]  

  • 37. Baby steps towards gene therapy for humans.
    Marron K
    Lab Anim (NY); 2008 Nov; 37(11):484. PubMed ID: 18948980
    [No Abstract]   [Full Text] [Related]  

  • 38. AAV-dependent targeting of myostatin function: follistatin strikes back at muscular dystrophy.
    Colussi C; Gaetano C; Capogrossi MC
    Gene Ther; 2008 Aug; 15(15):1075-6. PubMed ID: 18528431
    [No Abstract]   [Full Text] [Related]  

  • 39. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.
    Muntoni F;
    Neuromuscul Disord; 2010 May; 20(5):355-62. PubMed ID: 20347306
    [No Abstract]   [Full Text] [Related]  

  • 40. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
    Finsterer J; Stöllberger C
    Neuromuscul Disord; 2009 Jan; 19(1):74; author reply 75. PubMed ID: 19070488
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.